All In Biotech

Drug Trial Radar · NCT03669588

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness

Last checked: Nov 20, 2026Latest source record: Feb 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 167 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

167

Actual

Start

Aug 22, 2018

Primary completion

Apr 6, 2020

Study completion Apr 6, 2020

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Sep 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • ARGX-113Biological

    Intravenous administration of ARGX-113

  • PlaceboBiological

    Intravenous administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive PopulationTime frame: Baseline up to Day 63 (end of TC1)

Locations

66 sites in 16 countries. Site status is shown where the registry gives one.

  • Investigator Site 29

    Phoenix, Arizona

  • Investigator Site 66

    Carlsbad, California

  • Investigator Site 5

    Los Angeles, California

  • Investigator Site 49

    Los Angeles, California

  • Investigator Site 18

    Orange, California

  • Investigator Site 40

    Palo Alto, California

  • Investigator Site 59

    San Francisco, California

  • Investigator Site 58

    Aurora, Colorado

  • Investigator Site 34

    Jacksonville, Florida

  • Investigator Site 4

    Tampa, Florida

  • Investigator Site 30

    Springfield, Illinois

  • Investigator Site 25

    Iowa City, Iowa

  • Investigator Site 21

    Kansas City, Kansas

  • Investigator Site 27

    Boston, Massachusetts

  • Investigator Site 48

    Detroit, Michigan

  • Investigator Site 53

    Buffalo, New York

  • Investigator Site 3

    Chapel Hill, North Carolina

  • Investigator Site 20

    Cleveland, Ohio

  • Investigator Site 9

    Portland, Oregon

  • Investigator Site 17

    Charleston, South Carolina

  • Investigator Site

    Cordova, Tennessee

  • Investigator Site 44

    Houston, Texas

  • Investigator Site 6

    San Antonio, Texas

  • Investigator Site 2

    Charlottesville, Virginia

  • Investigator Site 16

    Seattle, Washington

  • Investigator Site 11

    Edegem, Belgium

  • Investigator Site 8

    Ghent, Belgium

  • Investigator Site 38

    Edmonton, Alberta, Canada

  • Investigator Site 24

    Toronto, Ontario, Canada

  • Investigator Site 22

    Montreal, Quebec, Canada

  • Investigator Site 32

    Brno, Czechia

  • Investigator Site 35

    Ostrava-Poruba, Czechia

  • Investigator Site 51

    Prague, Czechia

  • Investigator Site 36

    Aarhus, Denmark

  • Investigator Site 15

    Copenhagen, Denmark

  • Investigator Site 13

    Bordeaux, France

  • Investigator Site 52

    Marseille, France

  • Investigator Site 46

    Tbilisi, Georgia

  • Investigator Site 45

    Tbilisi, Georgia

  • Investigator Site 47

    Tbilisi, Georgia

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.